摘要：Inspired by the limitations of nanoparticles in cancer treatment caused by their low therapeutic effects and biotoxicity,biocompatible and photothermal enhanced copper oxide-decorated carbon nanospheres(CuO@CNSs)with doxorubicin hydrochloride(DOX)loading were *** as photothermal agents were synthesized by a hydrothermal *** was adsorbed on the surface of CNSs,which improved the photothermal conversion efficiency due to the electron transitions between C-2 p and Cu-3 *** addition,CuO would release Cu2+ions in the tumor microenvironment,which could produce hydroxyl radical(·OH)to induce cancer cells apoptosis via Haber-Weiss and Fenton-like *** as a chemotherapeutic agent was located on the surface of CuO@CNSs by electrostatic adsorption and released quickly in the tumor microenvironment to kill cancer *** CuO@CNSs-DOX nanoplatforms realized the combination therapy of photothermal therapy(PTT),chemodynamic therapy(CDT),and chemotherapy(CT),which have strong potential for cancer treatment.

摘要：Antibacterial nanoagents with broad-spectrum antibacterial activities have emerged as an evolution of ***,their bacteria-capturing capability and bacteria-killing efficiency remain insufficient for commercial *** by the hunting behavior of spiders,here,a novel spiderweb-like nanoagent based on silver-adenine nanowires is designed to achieve high-efficiency capture and killing of *** virtue of the initiative bacteriacapturing functionality,this spiderweb-like nanoagent could effectively attract and trap bacteria through electrostatic interaction and its reticular morphology ***,its synergetic antibacterial mechanism combining physical membranolysis with reactive oxygen species(ROS)release allows such nanoagent to harvest a promoted bactericidal ***,the woundplast employing the spiderweblike nanoagent exhibits a superior antibacterial efficacy against drug-resistant Gram-negative Escherichia coli and Gram-positive methicillin-resistant Staphylococcus aureus compared with commercially available *** work may pave a new way for rational design of new generation bactericidal agents facing the future super-bacteria booming.

摘要：Peptide inhibition of the interactions of the tumor suppressor protein P53 with its negative regulators MDM2 and MDMX activates P53 in vitro and in vivo,representing a viable therapeutic strategy for cancer *** phage display techniques,we previously identified a potent peptide activator of P53,termed PMI(TSFAEYWNLLSP),with binding affinities for both MDM2 and MDMX in the low nanomolar concentration *** we report an ultrahigh affinity,dual-specificity peptide antagonist of MDM2 and MDMX obtained through systematic mutational analysis and additivitybased molecular *** assays of over 100 peptide analogs of PMI using surface plasmon resonance and fluorescence polarization techniques yielded a dodecameric peptide termed PMI-M3(LTFLEYWAQLMQ)that bound to MDM2 and MDMX with K_(d)values in the low picomolar concentration range as verified by isothermal titration ***-crystal structures of MDM2 and of MDMX in complex with PMI-M3 were solved at 1.65 and 3.0 A resolution,*** to PMI,PMI-M3 occupied the P53-binding pocket of MDM2/MDMX,which was dominated energetically by intermolecular interactions involving Phe3,Tyr6,Trp7,and Leu *** differences in binding between PMI-M3 and PMI were observed at other positions such as Leu4 and Met11 with MDM2,and Leu1 and Met11 with MDMX,collectively contributing to a significantly enhanced binding affinity of PMI-M3 for both *** adding lysine residues to both ends of PMI and PMI-M3 to improve their cellular uptake,we obtained modified peptides termed PMI-2K(KTSFAEYWNLLSPK)and M3-2K(KLTFLEYWAQLMQK).Compared with PMI-2K,M3-2K exhibited significantly improved antitumor activities in vitro and in vivo in a P53-dependent *** super-strong peptide inhibitor of the P53-MDM2/MDMX interactions may become,in its own right,a powerful lead compound for anticancer drug development,and can aid molecular design of other classes of P53 activators as well for anticancer therapy.